TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS.

Charicleia Kelaidi, Lionel Ades, Pierre Fenaux
  • Charicleia Kelaidi
    Department of Hematology, G. Papanikolaou Hospital of Thessaloniki, Exochi 57010, Greece., Greece | charikleia.kelaidi@gmail.com
  • Lionel Ades
    Affiliation not present
  • Pierre Fenaux
    Service d’Hématologie, Hôpital Avicenne - Université Paris 13, France

Abstract

Acute promyelocytic leukemia (APL) with WBC above 10 G/L has long been considered, even in the all-trans retinoic acid (ATRA) era, to carry a relatively poor prognosis (compared to  APL with WBC below 10 G/L), due to increased early mortality and relapse. However, early deaths can to a large extent be avoided if specific measures are rapidly instigated, including prompt referral to a specialized center, immediate onset of ATRA and chemotherapy, treatment of coagulopathy with adequate platelet transfusional support, and prevention and management of differentiation syndrome. Strategies to reduce relapse rate include chemotherapy reinforcement with cytarabine and/or arsenic trioxide during consolidation, prolonged maintenance treatment, especially with ATRA and low dose chemotherapy, and possibly, although this is debated, intrathecal prophylaxis to prevent central nervous system relapse. By applying those measures, outcomes of patients with high risk APL have considerably improved, and have become in many studies almost similar to those of standard risk APL patients.

 

Keywords

Leukemia, Promyelocytic Leukemia, Hyperleucocytosysis

Full Text:

PDF
HTML
Submitted: 2014-06-12 16:03:38
Published: 2011-09-08 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
501

Views:
PDF
163
HTML
1252

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2016 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

The Mediterranean Journal of Hematology and Infectious Diseases [eISSN 2035-3006] is owned by the U.C.S.C. and it is published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.
 
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185